-DOCSTART- -X- O
Zika -X- _ O
virus -X- _ O
( -X- _ O
ZIKV -X- _ O
) -X- _ O
is -X- _ O
a -X- _ O
human-pathogenic -X- _ O
flavivirus -X- _ O
that -X- _ O
has -X- _ O
recently -X- _ O
emerged -X- _ O
as -X- _ O
a -X- _ O
global -X- _ O
public -X- _ O
health -X- _ O
threat. -X- _ O
ZIKV -X- _ O
infection -X- _ O
may -X- _ O
be -X- _ O
associated -X- _ O
with -X- _ O
congenital -X- _ O
malformations -X- _ O
in -X- _ O
infected -X- _ O
fetuses -X- _ O
and -X- _ O
severe -X- _ O
neurological -X- _ O
and -X- _ O
systemic -X- _ O
complications -X- _ O
in -X- _ O
infected -X- _ O
adults. -X- _ O
There -X- _ O
are -X- _ O
currently -X- _ O
limited -X- _ O
treatment -X- _ O
options -X- _ O
for -X- _ O
ZIKV -X- _ O
infection. -X- _ O
AR-12 -X- _ O
( -X- _ O
OSU-03012 -X- _ O
) -X- _ O
is -X- _ O
a -X- _ O
celecoxib -X- _ O
derivative -X- _ O
cellular -X- _ O
kinase -X- _ O
inhibitor -X- _ O
that -X- _ O
has -X- _ O
broad-spectrum -X- _ O
antiviral -X- _ O
activities. -X- _ O
In -X- _ O
this -X- _ O
study -X- _ O
, -X- _ O
we -X- _ O
investigated -X- _ O
the -X- _ O
antiviral -X- _ O
activity -X- _ O
and -X- _ O
mechanism -X- _ O
of -X- _ O
AR-12 -X- _ B-Intervention
against -X- _ O
ZIKV. -X- _ O
We -X- _ O
evaluated -X- _ O
the -X- _ O
in -X- _ O
vitro -X- _ O
anti-ZIKV -X- _ O
activity -X- _ O
of -X- _ O
AR-12 -X- _ B-Intervention
, -X- _ O
using -X- _ O
cell -X- _ O
protection -X- _ O
and -X- _ O
virus -X- _ O
yield -X- _ O
reduction -X- _ O
assays -X- _ O
, -X- _ O
in -X- _ O
multiple -X- _ O
clinically -X- _ O
relevant -X- _ O
cell -X- _ O
lines -X- _ O
, -X- _ O
and -X- _ O
the -X- _ O
in -X- _ O
vivo -X- _ O
treatment -X- _ O
effects -X- _ O
of -X- _ O
AR-12 -X- _ B-Intervention
in -X- _ O
a -X- _ O
lethal -X- _ O
mouse -X- _ O
model -X- _ O
using -X- _ O
type -X- _ B-Patient
I -X- _ I-Patient
interferon -X- _ I-Patient
receptor-deficient -X- _ I-Patient
A129 -X- _ I-Patient
mice. -X- _ I-Patient
AR-12 -X- _ B-Outcome
inhibited -X- _ I-Outcome
ZIKV -X- _ I-Outcome
strains -X- _ I-Outcome
belonging -X- _ I-Outcome
to -X- _ I-Outcome
both -X- _ I-Outcome
the -X- _ I-Outcome
African -X- _ I-Outcome
and -X- _ I-Outcome
Asian -X- _ I-Outcome
/ -X- _ I-Outcome
American -X- _ I-Outcome
lineages -X- _ I-Outcome
in -X- _ I-Outcome
Huh-7 -X- _ I-Outcome
and -X- _ I-Outcome
/ -X- _ I-Outcome
or -X- _ I-Outcome
neuronal -X- _ I-Outcome
cells. -X- _ I-Outcome
AR12 -X- _ I-Outcome
's -X- _ I-Outcome
IC50 -X- _ I-Outcome
against -X- _ I-Outcome
ZIKV -X- _ I-Outcome
was -X- _ I-Outcome
consistently -X- _ I-Outcome
< -X- _ I-Outcome
2 -X- _ I-Outcome
μM -X- _ I-Outcome
in -X- _ I-Outcome
these -X- _ I-Outcome
cells. -X- _ I-Outcome
ZIKV-infected -X- _ I-Outcome
A129 -X- _ I-Outcome
mice -X- _ I-Outcome
treated -X- _ I-Outcome
with -X- _ I-Outcome
intraperitoneally -X- _ I-Outcome
or -X- _ I-Outcome
orally -X- _ I-Outcome
administered -X- _ I-Outcome
AR-12 -X- _ I-Outcome
had -X- _ I-Outcome
significantly -X- _ I-Outcome
higher -X- _ I-Outcome
survival -X- _ I-Outcome
rate -X- _ I-Outcome
( -X- _ I-Outcome
50.0 -X- _ I-Outcome
% -X- _ I-Outcome
–83.3 -X- _ I-Outcome
% -X- _ I-Outcome
vs -X- _ I-Outcome
0 -X- _ I-Outcome
% -X- _ I-Outcome
, -X- _ I-Outcome
P -X- _ I-Outcome
< -X- _ I-Outcome
0.05 -X- _ I-Outcome
) -X- _ I-Outcome
, -X- _ I-Outcome
less -X- _ I-Outcome
body -X- _ I-Outcome
weight -X- _ I-Outcome
loss -X- _ I-Outcome
, -X- _ I-Outcome
and -X- _ I-Outcome
lower -X- _ I-Outcome
blood -X- _ I-Outcome
and -X- _ I-Outcome
tissue -X- _ I-Outcome
ZIKV -X- _ I-Outcome
RNA -X- _ I-Outcome
loads -X- _ I-Outcome
than -X- _ I-Outcome
untreated -X- _ I-Outcome
control -X- _ I-Outcome
A129 -X- _ I-Outcome
mice. -X- _ I-Outcome
These -X- _ O
anti-ZIKV -X- _ O
effects -X- _ O
were -X- _ O
likely -X- _ O
the -X- _ O
results -X- _ O
of -X- _ O
down-regulation -X- _ O
of -X- _ O
the -X- _ O
PI3K -X- _ O
/ -X- _ O
Akt -X- _ O
pathway -X- _ O
by -X- _ O
AR-12. -X- _ O
Clinical -X- _ O
trials -X- _ O
using -X- _ O
the -X- _ O
clinically -X- _ O
available -X- _ O
and -X- _ O
broad-spectrum -X- _ O
AR-12 -X- _ O
as -X- _ O
an -X- _ O
empirical -X- _ O
treatment -X- _ O
should -X- _ O
be -X- _ O
considered -X- _ O
especially -X- _ O
for -X- _ O
patients -X- _ O
residing -X- _ O
in -X- _ O
or -X- _ O
returning -X- _ O
from -X- _ O
areas -X- _ O
endemic -X- _ O
of -X- _ O
ZIKV -X- _ O
and -X- _ O
other -X- _ O
arboviral -X- _ O
infections -X- _ O
who -X- _ O
present -X- _ O
with -X- _ O
an -X- _ O
acute -X- _ O
undifferentiated -X- _ O
febrile -X- _ O
illness -X- _ O
. -X- _ O

